Dusseldorf - Delayed Quote EUR

RI2.DU,0P0001MXZE,0 (RI2.DU)

7.61

0.00

(0.00%)

As of July 23 at 10:00:00 PM GMT+2. Market Open.

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

PR Newswire 2 days ago

RIGL
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 23,350 stock options and restricted stock units to seven non-executive employees vesting over four years w

PR Newswire 27 days ago

RIGL
High Growth Tech Stocks in the US for April 2025

Over the last 7 days, the United States market has dropped 5.6%, yet it remains up by 3.3% over the past year, with earnings projected to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves focusing on companies that can capitalize on robust earnings potential and demonstrate resilience amid recent market fluctuations.

Simply Wall St. 27 days ago

RDVT

CKPT

RIGL
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively "Annora") resolving patent litigation related to Rigel's product TAVALISSE® (fostamatinib disodium hexahydrate). The litigation resulted from submission by Annora of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of TAVALISSE

PR Newswire last month

RIGL
Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are

Even though Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) posted strong earnings, investors appeared to be underwhelmed...

Simply Wall St. last month

RIGL
Rigel Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations

Rigel Pharmaceuticals ( NASDAQ:RIGL ) Full Year 2024 Results Key Financial Results Revenue: US$179.3m (up 55% from FY...

Simply Wall St. last month

RIGL
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy.

PR Newswire last month

RIGL
Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders are probably feeling a little disappointed, since its shares...

Simply Wall St. last month

RIGL
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia (ITP); REZLIDHIA® (olutasidenib) for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML);

PR Newswire last month

RIGL
High Growth Tech Stocks In The US Market To Watch

Over the last 7 days, the United States market has dropped 3.6%, yet over the longer term, it has risen by 17% in the last year with earnings forecasted to grow by 14% annually. In light of these conditions, identifying high growth tech stocks involves looking for companies with strong innovation potential and robust financial health that can capitalize on future earnings growth.

Simply Wall St. 2 months ago

COMM

GRND

RIGL
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

PR Newswire 2 months ago

RIGL
With 57% ownership of the shares, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is heavily dominated by institutional owners

Key Insights Given the large stake in the stock by institutions, Rigel Pharmaceuticals' stock price might be vulnerable...

Simply Wall St. 2 months ago

RIGL
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamatinib, the company's oral spleen tyrosine kinase (SYK) inhibitor, in patients with sickle cell disease (SCD). The study is being sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institute of Health (NIH). Fostamatinib, marketed in the U.S. as TAVALISSE® (fostamatinib disodium

PR Newswire 3 months ago

RIGL
Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has experienced a 2.1% drop, yet it remains up by 21% over the past year with earnings projected to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on evolving market trends.

Simply Wall St. 3 months ago

RIGL

SPRY

HCP
Rigel Provides Business Update and 2025 Outlook

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2024, ongoing activity from the commercial business and development pipeline, and its financial outlook for 2025.

PR Newswire 3 months ago

RIGL
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). R2891, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients

PR Newswire 3 months ago

RIGL
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA.

PR Newswire 3 months ago

RIGL
Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year

The Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) share price has had a bad week, falling 26%. But that doesn't change...

Simply Wall St. 4 months ago

RIGL
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS). The data is being presented today by Dr. Guillermo Garcia-Manero (Poster #: 4595) at the 66th American Society of He

PR Newswire 4 months ago

RIGL
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R2891, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety,

PR Newswire 4 months ago

RIGL

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

RI2.DU,0P0001MXZE,0 (RI2.DU)

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

High Growth Tech Stocks in the US for April 2025

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are

Rigel Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

High Growth Tech Stocks In The US Market To Watch

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

With 57% ownership of the shares, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is heavily dominated by institutional owners

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Exploring Three High Growth Tech Stocks In The United States

Rigel Provides Business Update and 2025 Outlook

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS